Table 4 Hurdle model exploring factors associated with observed HAT prevalence (all projects combined)

Screening coverage (%)

5-14

16 (5)

0.28†

0.09-0.89

3.39†

β _c

1.25-9.21

15-24

38 (19)

0.52

0.25-1.09

2.83

1.58-5.04

25-34

44 (31)

0.78

0.37-1.63

1.77

0.95-3.27

35-44

65 (37)

0.64

0.32-1.28

1.49

0.79-2.81

45-54

74 (46)

0.74

0.37-1.49

1.49

0.85-2.64

55-64

64 (46)

1.18

0.60-2.35

1.47

0.78-2.76

65-74

66 (47)

1.08

0.54-2.17

1.25

0.70-2.24

75-84

66 (46)

0.89

0.44-1.82

1.12

0.62-2.03

85-94

44 (27)

0.79

0.37-1.66

1.19

0.61-2.35

95-104

22 (16)

1

[reference]

1

[reference]

105-199

59 (33)

0.95

0.45-2.00

0.69

0.36-1.32

≥200

46 (25)

1.61

0.65-3.99

0.34

0.15-0.78

Screening round

first round

246 (176)

1

[reference]

1

[reference]

subsequent rounds

358 (202)

0.56

0.44-0.71

0.58

0.47-0.72

Village population size

<100

38 (12)

1†

[reference]

1†

[reference]

100-499

141 (71)

1.98

0.91-4.26

0.50

0.26-0.94

500-999

166 (111)

3.07

1.31-7.20

0.34

0.16-0.71

≥1000

259 (184)

3.84

1.60-9.19

0.23

0.11-0.49

Observed incidence rate in the past 6 months (cases per 1000 person-months)

0.00

239 (100)

1

[reference]

1†

[reference]

0.01-0.99

263 (201)

2.38

1.80-3.15

1.45

1.20-1.77

1.00-4.99

86 (63)

3.04

2.11-4.37

3.40

2.47-4.68

≥5.00

16 (14)

6.08

3.15-11.73

6.16

3.84-9.87

Project

Adjumani

320 (215)

1

[reference]

1

[reference]

Arua-Yumbe

142 (104)

0.77

0.54-1.10

0.40

0.27-0.59

Kiri

142 (59)

0.65

0.41-1.05

1.02

0.70-1.48

p (goodness of fit): <0.0001

p (goodness of fit): <0.0001